Lisanti Capital Growth LLC acquired a new position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) in the fourth quarter, Holdings Channel reports. The firm acquired 212,935 shares of the medical research company’s stock, valued at approximately $3,445,000. A number of other hedge funds and other institutional investors have also recently added to or reduced their […]
Lisanti Capital Growth LLC acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 212,935 shares of the medical research company’s stock, valued at approximately $3,445,000. Lisanti Capital Growth LLC owned approximately 0.17% […]
Handelsbanken Fonder AB lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 7.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,900 shares of the medical research company’s stock after acquiring an additional 1,300 shares during the period. Handelsbanken Fonder AB’s holdings in NeoGenomics were worth $322,000 as of […]
Benchmark reaffirmed their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $18.00 price objective on the medical research company’s stock. Other research analysts also recently issued reports about the company. William Blair restated an outperform rating […]
Benchmark reissued their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $18.00 price target on the medical research company’s stock. A number of other brokerages have also commented on NEO. Piper Sandler increased their price objective on NeoGenomics from $18.00 […]